Connor, Clark & Lunn Investment Management Ltd. Prothena Corp Public LTD CO Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$26 Billion
Q2 2025

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 18,896 shares of PRTA stock, worth $193,117. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,896

Previous 91,482 79.34%

Holding current value

$193,117

Previous $1.13 Million 89.93%

% of portfolio

0.0%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 07, 2025	SELL	$4.58 - $12.14 $332,443 - $881,194	-72,586 Reduced 79.34%	18,896 $114,000
Q1 2025 May 12, 2025	SELL	$12.38 - $16.04 $4,432 - $5,742	-358 Reduced 0.39%	91,482 $1.13 Million
Q4 2024 Feb 10, 2025	SELL	$11.95 - $18.35 $366,291 - $562,464	-30,652 Reduced 25.02%	91,840 $1.27 Million
Q3 2024 Nov 08, 2024	BUY	$16.73 - $24.79 $161,712 - $239,620	9,666 Added 8.57%	122,492 $2.05 Million
Q2 2024 Aug 09, 2024	SELL	$19.54 - $26.15 $372,803 - $498,915	-19,079 Reduced 14.46%	112,826 $2.33 Million
Q1 2024 May 09, 2024	SELL	$24.75 - $40.66 $594,915 - $977,344	-24,037 Reduced 15.41%	131,905 $3.27 Million
Q4 2023 Feb 09, 2024	BUY	$32.31 - $52.32 $910,075 - $1.47 Million	28,167 Added 22.04%	155,942 $5.67 Million
Q3 2023 Nov 13, 2023	BUY	$47.3 - $70.6 $834,324 - $1.25 Million	17,639 Added 16.02%	127,775 $6.17 Million
Q2 2023 Aug 10, 2023	BUY	$48.26 - $78.59 $999,561 - $1.63 Million	20,712 Added 23.16%	110,136 $7.52 Million
Q1 2023 May 09, 2023	BUY	$46.97 - $58.27 $1.36 Million - $1.69 Million	28,992 Added 47.97%	89,424 $4.33 Million
Q4 2022 Feb 10, 2023	BUY	$52.05 - $65.0 $1.71 Million - $2.14 Million	32,876 Added 119.31%	60,432 $3.64 Million
Q3 2022 Nov 10, 2022	BUY	$25.16 - $60.63 $289,994 - $698,821	11,526 Added 71.9%	27,556 $1.67 Million
Q2 2022 Aug 05, 2022	BUY	$22.73 - $39.98 $364,361 - $640,879	16,030 New	16,030 $435,000
Q4 2021 Feb 10, 2022	SELL	$42.11 - $73.26 $281,715 - $490,109	-6,690 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$48.2 - $78.89 $322,458 - $527,774	6,690 New	6,690 $477,000
Q2 2020 Aug 13, 2020	SELL	$9.56 - $12.51 $250,711 - $328,074	-26,225 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$7.54 - $15.77 $45,994 - $96,197	6,100 Added 30.31%	26,225 $280,000
Q4 2019 Feb 12, 2020	SELL	$7.48 - $17.01 $28,424 - $64,638	-3,800 Reduced 15.88%	20,125 $319,000
Q3 2019 Nov 13, 2019	BUY	$6.89 - $10.45 $31,521 - $47,808	4,575 Added 23.64%	23,925 $188,000
Q2 2019 Aug 07, 2019	BUY	$8.85 - $12.49 $171,247 - $241,681	19,350 New	19,350 $205,000

Others Institutions Holding PRTA

# of Institutions

220

Shares Held

34.4M

Call Options Held

879K

Put Options Held

791K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $480M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Prothena Corp Public LTD CO Transaction History